Ruti Aga gets six-year ban: family member forged the prescription, and a 2:18-class marathon career is effectively over

Ethiopian marathon runner Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU), according to a statement issued on Thursday. The sanction is built from two separate violations: two years for the presence of a prohibited substance, and four years for tampering with evidence during the investigation. The two add up to six years, counted from 10 September — the same date on which she was provisionally suspended. The case begins with a half marathon in China in March, which Aga won. A sample taken in-competition returned methylprednisolone. Aga's defence rested on treatment for a knee injury, and she produced a prescription to support it. Investigators found the prescription to be forged. According to the AIU, it was prepared by a family member who held no medical registration. That document, not the substance, is what turned a likely two-year absence into a six-year ban. The most important technical point, and one the early reporting got wrong: methylprednisolone is not an anabolic steroid. It is a glucocorticoid, listed under class S9 of the WADA Prohibited List, and under current rules it is prohibited in-competition only — and only when injected, taken orally, or administered rectally. Calling it a performance-enhancing steroid is inaccurate and blurs the legal hinge of the case. A therapeutic knee injection is entirely legal out-of-competition; it becomes a violation only if residues are present in an in-competition sample. The entire matter therefore turned on route of administration and timing relative to the race, not on 'steroid use.' And that is precisely where Aga destroyed her strongest defence. With genuine medical records, a documented injection date and a clear route of administration, the presence charge could plausibly have been argued at the no-fault or no-significant-fault end of the scale — a reprimand or a substantially reduced period — and a tampering charge would not have arisen at all. By submitting a fabricated document, she closed the one path that could have saved her. The construction of the forgery is striking in itself. The AIU investigation established that the clinic named on the prescription did not exist; the person who signed as 'doctor' had no medical registration; and when questioned, that person claimed to have used 'an old prescription pad from a former workplace' which the clinic explicitly disowned. Three independent verification checks, three failures. This was not a clerical slip; it was a document designed to collapse on first inspection. The true root cause is the knee injury. Chronic knee pathology is not an exception in distance running but a professional hazard, and glucocorticoid injection is its most common, cheapest and most accessible treatment. For marathoners, racing through pain is economically rational — appearance fees, sponsor expectations, ranking continuity. But both the legitimacy of the treatment and its documentation require organised medical support, and that support is conspicuously absent around Aga. No therapeutic use exemption appears to have been sought, no washout period for the prohibited substance is visible, and no registered team physician is in evidence. When the 'doctor' administering the injection is a family member and the record is a forged pad, this is a systems failure rather than an individual lapse. From a career standpoint the sanction is functionally a lifetime ban. Aga is 32. A return in six years would come at roughly 38 — and in Ethiopian women's marathon, depth is so extreme that a 38-year-old with a doping record is effectively unselectable. The 2028 Olympic cycle is closed to her entirely. Note also that the ban is anchored to the March race; earlier results are not automatically annulled, so the 2026 Tokyo Marathon title and three World Marathon Majors second places remain on the record. The AIU has not stated the scope of disqualification, but standard practice would void the result and prize money from the competition at which the sample was collected. The arithmetic of the sanction is itself informative. Two years for presence plus four for tampering matches the Code's standard architecture. Two years implies the panel treated the substance as a specified substance without proven intent, but declined to accept any meaningful mitigation. Four years is the standard tampering sanction. Crediting the period of provisional suspension is a procedural benefit, but in real terms it gives the athlete nothing. A larger question hangs over the outcome: how does a glucocorticoid — a substance with no proven endurance benefit — produce a six-year ban? The decision will be read two ways: as evidence of AIU rigour, and as evidence of disproportionate enforcement against African road runners. That debate will be sharp, because this is exactly the class of substance where legitimate therapeutic use remains possible — and the forged document eliminated that possibility. The competitive picture is essentially unaffected. The removal of a 2:18–2:20 class runner from Ethiopian women's marathon does not change national-team capacity by any measurable margin; her three Major podiums were commercial-tier results, not championship conversions. The real shift is in the enforcement landscape. Because this case is not isolated. A pattern is visible across recent AIU road-racing cases: an initial substance violation, followed by a fabricated or altered explanation. The enforcement frontier has moved from detection to document verification. China's label-race circuit sits at the centre of that shift — large appearance-fee budgets, deep East African elite fields and AIU testing all converge in the same races. Where money and testing coincide, integrity risk will be highest. Aga retains the right of appeal to the CAS, typically within about 21 days of the reasoned decision. But the tampering finding is document-based and extremely difficult to overturn. In practical terms, the case is closed. The lesson that survives is plain: what ended this athlete's career was not the substance. A legitimate treatment, clean records and correct timing could have saved her. What she chose instead was a document that the very clinic named on it disowned — and six years is the price of that single decision.